Compare Ascendis Pharma A/S (ASND) vs Carvana Co (CVNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Carvana Co — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Carvana Co trades at $65.73 (market cap $47.15B). The key difference: Carvana Co is far larger — about 2.7× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| ASND | CVNA | |
|---|---|---|
Market Cap | $17.74B | $47.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $95.69 |
52-Week Low | $163.32 | $56.27 |
Enterprise Value | $18.11B | $49.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Carvana (CVNA) trades at $65.83, down 1.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $20.32B in 2025 and net income of $1.41B, though Q2 2026 earnings are pending. Recent corporate actions include stock splits, and positive news highlights expansion into new-car sales and same-day delivery services. The stock shows improving cash flow trends, with operating cash flow reaching $1.04B in 2025.
Outlook: CVNA presents a mixed picture with robust revenue growth and profitability improvements offset by high valuation multiples and technical bearishness. Investment opportunity lies in continued operational scaling and market expansion, but risks include debt levels and competitive pressures. Analysts maintain a bullish consensus price target of $93.92, suggesting potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
